

## Compositions and Methods for Treating Neurological Diseases

This application claims the benefit of the filing date of U.S. Serial No. 60/518,474, filed November 7, 2003. For the purpose of any United States patent that may issue from the present application, the entire content of the prior provisional application is hereby 5 incorporated by reference herein.

### **STATEMENT AS TO FEDERALLY SPONSORED RESEARCH**

Some of the work described here was funded by a grant from the National Institutes of Health (R01AG020204). The United States government may, therefore, have certain 10 rights in the invention.

### **TECHNICAL FIELD**

The present invention relates to compositions and methods for treating patients who have been diagnosed as having a neurological disease. More particularly, the invention relates to compositions, including amplicon particles, that can be used to prevent 15 Alzheimer's disease (AD) or to ameliorate or reverse the progression of AD and its attendant symptoms.

### **BACKGROUND**

Alzheimer's Disease is a neurodegenerative disorder associated with gradual functional decline, dementia and neuronal loss that is initiated in specific brain regions and 20 advances in a disease-specific manner. Clinical hallmarks include progressive impairment in memory, judgment, decision-making, orientation to physical surroundings, and language, all of which vary considerably among afflicted individuals.

Although rare before the age of 50, AD affects nearly half of all people in the most rapidly growing portion of the U.S. population: those older than 85. As such, the current 25 number of AD patients in the United States is expected to increase greatly in the coming years.

There is presently no known method of preventing AD. Current therapies are primarily supportive, such as those provided by a family member in attendance. Stimulated memory exercises on a regular basis have been shown to slow, but not stop, memory loss.

A few drugs, such as tacrine (Cognex®), result in a modest temporary improvement of cognition but these drugs cannot stop the progressive dementia.

A hallmark of AD is the accumulation, in certain regions of the brain, of extracellular insoluble deposits called amyloid plaques, and abnormal lesions within 5 neuronal cells called neurofibrillary tangles. When present, these plaques and tangles provide the only basis for a definitive diagnosis of AD.

The major components of amyloid plaques are the amyloid  $\beta$ -peptides, also called A $\beta$  peptides, which consist of three proteins having 40, 42 or 43 amino acids, designated as the A $\beta_{1-40}$ , A $\beta_{1-42}$ , and A $\beta_{1-43}$  peptides, respectively. The amino acid sequences of the A $\beta$  10 peptides are known; the sequence of A $\beta_{1-42}$  identical to that of A $\beta_{1-40}$ , except that A $\beta_{1-42}$  contains two additional amino acid residues at its carboxyl terminus. Similarly, the amino acid sequence of A $\beta_{1-43}$  is identical to that of A $\beta_{1-42}$  except that A $\beta_{1-43}$  contains one additional amino acid at its carboxyl terminus. The A $\beta$  peptides are thought to cause the nerve cell destruction in AD, in part, because they are toxic to neurons *in vitro* and *in vivo*.

15 The A $\beta$  peptides are derived from larger amyloid precursor proteins (APP proteins), which consist of four proteins, designated as the APP<sub>695</sub>, APP<sub>714</sub>, APP<sub>751</sub>, and APP<sub>771</sub> proteins, which contain 695, 714, 751 or 771 amino acids, respectively. The different APP 20 proteins result from alternative ribonucleic acid splicing of a single APP gene product. The amino acid sequences of the APP proteins are also known and each APP protein contains the amino acid sequences of the A $\beta$  peptides.

Proteases, now referred to as secretases (e.g., BACE1) are believed to produce the A $\beta$  peptides by recognizing and cleaving specific amino acid sequences within the APP proteins. Such sequence-specific proteases are thought to produce the peptides consistently found in plaques.

25

## SUMMARY

The present invention is based, in part, on our discovery that administration of a protein that naturally occurs within the plaques that form in AD brains can be used in conjunction with an adjuvant to improve the status of that disease in a well accepted animal 30 model. A composition containing one or more naturally occurring A $\beta$  proteins, or antigenic fragments or other biologically active variants thereof, can therefore be used to prevent,

slow, or reverse the appearance of amyloid plaques and the onset or progression of AD or one or more of the signs and symptoms associated with neurological diseases such as AD. While the invention is not limited to proteins that work by any particular mechanism, we expect the compositions will induce or enhance an immune response in a patient to whom 5 they are administered (e.g., a humoral immune response or an immune response that lacks a substantial cytotoxic T cell response (e.g., an immune response skewed toward a T helper cell response)). The invention features compositions that contain A $\beta$  proteins (e.g., pharmaceutical compositions and kits), methods of making them, and methods of administering them to a patient (e.g., a human patient). Various embodiments are described 10 further below.

The methods of the invention include methods of treating a patient who has been diagnosed as having a neurodegenerative disease characterized by extracellular plaques (e.g., amyloid plaques or plaques containing an A $\beta$  protein) or the improper processing of APP. The methods can also be applied to a patient who is at risk of 15 developing such a disease. Thus, the methods can be carried out on patients who are apparently healthy or who show no signs of AD as well as patients who have been diagnosed with AD. While all individuals are at some risk of developing Alzheimer's disease, some have a heightened risk due to, for example, advanced age or family history. Various mutations in the APP or A $\beta$  proteins are known to be associated 20 with a greater risk of AD (e.g., the Swedish mutation in the APP protein). The Dutch and Iowa mutations are associated with early onset AD and appear in both the APP protein and the A $\beta$  proteins formed therefrom.

The precise way in which the treatment is carried out can vary so long as the patient receives a therapeutically effective amount of a composition that includes an 25 A $\beta$  protein (e.g., A $\beta$ <sub>1-40</sub>, A $\beta$ <sub>1-42</sub>, and/or A $\beta$ <sub>1-43</sub> (e.g., a human A $\beta$  protein)) or an antigenic fragment or other biologically active variant thereof (e.g., an A $\beta$  protein that includes the Dutch or Iowa mutation). In one embodiment, the patient is treated by administering an A $\beta$  protein or an antigenic fragment or other biologically active variant thereof (e.g., a substitution mutant). The protein can be presented as a linear 30 epitope or engineered to offer a conformational epitope (e.g., a sequence that is conformationally constrained to better mimic the three-dimensional structure of the

corresponding region on the antigen *in vivo*). For example, the A $\beta$  proteins can be cyclized and may contain additional residues to join the C- and N-termini (e.g., a di- or tri-peptide linker). The immunogenicity of the engineered A $\beta$  protein can be tested in numerous ways, including within an animal model of AD or in human volunteers.

5 Alternatively, or in addition, the patient can be treated by administering a cell (e.g., an antigen presenting cell (APC) such as a dendritic cell) that expresses on its surface at least a portion of an A $\beta$  protein or an antigenic fragment or other biologically active variant thereof. Alternatively, or in addition, the patient can be treated by administering a nucleic acid molecule that includes a sequence that encodes an A $\beta$

10 protein or an antigenic fragment or other biologically active variant thereof. For ease of reading, we do not continue to repeat the phrase “or an antigenic fragment or other biologically active variant thereof” at every opportunity. It is to be understood that where an A $\beta$  protein can be used, one can also use an antigenic fragment or other biologically active variant thereof (*i.e.*, a fragment, mutant, or other variant that

15 confers a clinical benefit on a patient (e.g., a patient believed to have AD)). The term “A $\beta$  protein” encompasses antigenic fragments and other biologically active variants thereof. These fragments and variants are described further below.

Regardless of the manner in which the A $\beta$  protein is administered, it can be administered with an adjuvant. We may use the terms “adjuvant” or “molecular adjuvant” to refer to a substance (e.g., a protein or lipid) that amplifies a given response (e.g., an immune response or a clinical endpoint (e.g., an improvement in a cognitive function)) beyond the response that would typically occur in the absence of adjuvant. Amplification may be evident where, for example, on average, the immune response or the improvement in a patient’s symptoms following the use of an adjuvant is as robust as that observed with a larger amount of antigen (*i.e.*, A $\beta$  protein) but no adjuvant. The adjuvant can be, for example, alum, tetanus toxoid (e.g., the C fragment of tetanus toxin (TtxFC)), keyhole limpet hemocyanin (KLH), aluminum hydroxide, aluminum phosphate, calcium phosphate, or an oil emulsion. Less traditional adjuvants include derivatives of muramyl dipeptide, monophosphoryl lipid A, liposomes, QS21, MF-59, and immunostimulating complexes (ISCOMS). The A $\beta$  proteins of the invention (or cells expressing them or nucleic acids encoding

them) can also be released in a controlled manner from biodegradable polymers (e.g., microspheres) and conjugated as protein-polysaccharide conjugates. *See Gupta and Siber, Vaccine 13:1263-1276, 1995.* Expressly excluded from the meaning of “adjuvant” are A $\beta$  proteins and the immunomodulatory proteins (e.g., 5 immunomodulatory cytokines) described below.

While we describe methods and routes of administration further below, we note here that the A $\beta$ -containing compositions can be administered orally or parenterally (e.g., by an intravenous, subcutaneous, or intramuscular injection). For example, an A $\beta$ -encoding nucleic acid can be placed within an expression vector such 10 as a plasmid, virus, or amplicon particle (e.g., a herpes virus amplicon particle such as a herpes simplex virus (HSV) amplicon, which may be made in a helper-free system (e.g., an HSVhf amplicon as described in the U.S. patent application published under number 20030027322)). Amplicon particles are able to contain large amounts of nucleic acid. Accordingly, they can be used to co-express the A $\beta$  protein, the 15 adjuvant (where proteinaceous), and an immunomodulatory protein (described further below). Once made or provided, the A $\beta$ -expressing vector can be injected into the patient. In the case of a herpes virus amplicon particle, components of the particle can be administered to the patient (as described further below). The amount 20 delivered, whether delivered once or as a “prime” followed by one or more “boosters” (given for a limited time (e.g., once or twice) or over an extended period of time (e.g., about once every 2-6 months) will be sufficient to improve one or more symptoms of the neurodegenerative disease. For example, the composition will be of a type and amount sufficient to improve one or more of the following symptoms: impaired memory, impaired thinking (e.g., impaired abstract thinking or forgetfulness 25 manifested by, for example, misplacing objects)), disorientation, confusion, difficulty performing familiar tasks, changes in personality, changes in behavior, impaired judgment, impaired ability to follow directions, impaired communication skills (e.g., impaired language skills), impaired visual skills, impaired spatial skills, loss of motivation or initiative, change from normal sleep patterns, or any other 30 relevant symptom of the neurological disease.

The A $\beta$  protein and the molecular adjuvant can be admixed, chemically conjugated, or fused (e.g., into a recombinant fusion polypeptide). Alternatively, the A $\beta$  protein and adjuvant can be maintained in separate containers and administered at the same time (or around the same time (e.g., sequentially)) by the same or different routes. Whether combined or provided separately, the compositions of the invention can be packaged with instructions (e.g., printed matter (e.g., written instructions or diagrams) and/or audio- and video instructions) as a kit. Optionally, the kit can provide paraphernalia for administering the composition(s) contained therein (e.g., syringes, needles, nebulizers, spray containers, alcohol swabs, and gauze or other dressing). For example, the invention features kits that include a vial containing one or more A $\beta$  proteins and an adjuvant. The A $\beta$  proteins and adjuvant may be concentrated or lyophilized and a diluent (e.g., a sterile, physiologically acceptable solution) may be provided in a separate vial. Alternatively, the A $\beta$  proteins and adjuvant can be suspended and ready for use. Other components of the kits include immunomodulatory proteins, as described below.

Any of the methods described above can include administration of an immunomodulatory protein (i.e., a protein other than an A $\beta$  protein or adjuvant). For example, in addition to administering an A $\beta$  protein or an A $\beta$  protein and an adjuvant, one can also administer an immunomodulatory cytokine that modulates the immune response to reduce the risk of inflammation (e.g., encephalitis). For example, one can also administer a chemokine such as RANTES; an interleukin such as interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-12 (IL-12), interleukin-15 (IL-15) or interleukin-23 (IL-23); an interferon or growth factor (e.g., granulocyte macrophage colony stimulating factor (GM-CSF), tumor necrosis factor alpha (TNF $\alpha$ ), or interferon- $\gamma$  (IFN $\gamma$ )); an intracellular adhesion molecule (e.g., ICAM-1 (also known as CD54), ICAM-2, or ICAM-3); or a costimulatory factor that activates B or T cells (e.g., B7.1). The chemokine can be one in the "C-C" family (e.g., MCP-1, MCP-2, MCP-3, DC-CK1, MIP-1 $\alpha$ , MIP-3 $\alpha$ , MIP-1 $\beta$ , MIP-3 $\beta$ ); one in the "C-X-C" family (e.g., IL-8, SDF-1 $\beta$ , SDF-1 $\alpha$ , GRO, PF-4 and MIP-2); one in the "C" family (e.g. lympotactin); or one in the "CX3C" family (e.g., fractalkine). As with the A $\beta$  proteins and proteinaceous adjuvants, the immunomodulatory proteins

can be administered as proteins *per se* (i.e., as pure or substantially pure proteins within the pharmaceutical composition), as proteins expressed on the surface of a cell, or as nucleic acids that are expressed *in vivo* as immunomodulatory proteins. Nucleic acid sequences encoding immunomodulatory proteins can be included in any of the 5 expression vectors described herein and may be included in the same vector or type of vector as the sequence encoding the A $\beta$  protein and/or the adjuvant. Similarly, while the immunomodulatory proteins can be full-length, naturally occurring proteins, they can also be biologically active variants thereof. For example, one can administer a fragment or other mutant of an immunomodulatory protein (e.g., a substitution 10 mutant) or a splice variant so long as the mutant or variant retains sufficient biological activity to confer a clinical benefit on the patient.

The invention also features compositions (e.g., pharmaceutically acceptable compositions) including any of those described above as suitable for use in the methods of treating a patient. For example, the compositions of the invention include A $\beta$  proteins 15 (e.g., A $\beta$ <sub>1-40</sub>, A $\beta$ <sub>1-42</sub>, and/or A $\beta$ <sub>1-43</sub> and/or antigenic fragments or biologically active variants thereof) with, optionally, a molecular adjuvant (including any specifically described herein). Compositions that include an A $\beta$  protein or an A $\beta$  protein and an adjuvant can further include an immunomodulatory protein. Where the proteins are expressed from a 20 delivery vehicle (e.g., a virus (e.g., a retrovirus or adenovirus), plasmid, or amplicon particle), that vehicle can constitute, or can constitute a part of, a composition of the invention (e.g., a pharmaceutical composition including a physiologically acceptable diluent (e.g., normal saline or phosphate-buffered saline (PBS))).

As noted above, the A $\beta$  protein, a proteinaceous antigen, and/or an 25 immunomodulatory protein may be expressed from the same delivery vehicle or same type of delivery vehicle as fused or unfused proteins. Accordingly, the invention encompasses delivery vehicles that include nucleic acid sequences encoding an A $\beta$  protein and a sequence encoding a molecular adjuvant (e.g., TtxFC or KLH) and/or an immunomodulatory protein (e.g., IL-2, IL-12, or IL-23). The delivery vehicles may further 30 include regulatory elements that facilitate the expression of the A $\beta$  protein, a proteinaceous adjuvant and/or an immunomodulatory protein.

In specific embodiments, the invention includes methods of treating a patient with a neurodegenerative disease associated with the presence of extracellular plaques (e.g., Alzheimer's disease) by administering to the patient (a) an amplicon plasmid or particle including an HSV origin of replication, an HSV cleavage/packaging signal, and a heterologous transgene expressible in a host cell, (b) one or more vectors that, individually or collectively, encode all essential HSV genes but exclude all cleavage/packaging signals, and (c) a vector encoding an accessory protein, in which the transgene encodes a therapeutic protein (e.g., a molecular adjuvant (e.g., TtcFC, KLH), an A $\beta$  protein, or both), that improves one or more symptoms of the neurodegenerative disease.

10 In specific embodiments, the invention features compositions for use as medicaments in treating a patient with a neurodegenerative disease (e.g., Alzheimer's disease) characterized by extracellular plaques, in which the compositions include (a) an amplicon plasmid including an HSV origin of replication, an HSV cleavage/packaging signal, and a heterologous transgene expressible in a host cell, (b) one or more vectors that, individually or collectively, encode all essential HSV genes but exclude all cleavage/packaging signals, and (c) a vector encoding an accessory protein, in which the transgene encodes a therapeutic protein (e.g., a molecular adjuvant (e.g., TtxFC, KLH, A $\beta$ , or both) that improves one or more symptoms of the neurodegenerative disease.

15 The invention additionally includes uses of compositions for the manufacture of a medicament for use in treating a patient with a neurodegenerative disease (e.g., Alzheimer's disease) characterized by extracellular plaques, in which the compositions includes (a) an amplicon plasmid including an HSV origin of replication, an HSV cleavage/packaging signal, and a heterologous transgene expressible in a host cell, (b) one or more vectors that, individually or collectively, encode all essential HSV genes but exclude all cleavage/packaging signals, and (c) a vector encoding an accessory protein, in which the transgene encodes a therapeutic protein (e.g., a molecular adjuvant (e.g., TtxFC or KLH), A $\beta$ , or both) that improves one or more symptoms of the neurodegenerative disease.

20 Our studies indicate that the treatment methods described herein will benefit at least some patients in ways that are not readily achieved by present treatments or therapies. For example, the present treatment could slow or stop the accumulation of A $\beta$  plaques and may

even reverse their size or number, thus providing substantial and prolonged improvement of the symptoms of AD. Moreover, the present treatment is expected to accomplish this desirable effect in humans without causing substantial inflammation in the patient's brain. Thus, the present methods may be more effective and safer than current methods.

5 Furthermore, by providing model organisms, this invention allows the further development of treatments for Alzheimer's disease.

Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references 10 mentioned herein are incorporated by reference in their entirety, including United States Patent Application Serial Nos. 09/997,848 and 10/296,551, and United States Provisional Patent Application Serial Nos. 60/250,079, 60/385,230, 60/442,030, and 60/480,112, especially as their disclosures relate to making and using HSV amplicons.. The details of one or more embodiments of the invention are set forth in the accompanying drawings and 15 the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIGs. 1A and 1B are schematic representations of amplicon vectors and the study 20 design. FIG 1A depicts two novel HSV amplicons plasmids that were constructed: one that expresses the A $\beta$ <sub>1-42</sub> peptide derived from APP (HSV $\alpha$  $\beta$ ), and another that expresses A $\beta$ <sub>1-42</sub> fused in-frame at the C-terminus with tetanus toxin Fragment C (HSV $\alpha$  $\beta$ /TtxFC). A previously described amplicon that expressed  $\beta$ -galactosidase (Geller and Breakefield, *Science* 241:1667-9, 1988; HSVlac) served as a control vector. All amplicons were 25 packaged using a previously described helper virus-free method (Bowers *et al.*, *Gene Ther.* 8, 2001). FIG 1B depicts how each packaged vector (1 x 10<sup>5</sup> transduction units) was delivered subcutaneously (s.c.) to APP<sub>Swe</sub>-overexpressing transgenic mice (Hsiao *et al.*, *Science* 274(5284):99-102, 1996; Tg2576) or non-transgenic littermates at 4-8 weeks of 30 age. Amplicons were administered monthly to each animal three times, and humoral assessments were performed one week post-injection and subsequently at one-month intervals. Antibody isotype analysis was performed on sera obtained at the 4-month

timepoint. Treated mice were sacrificed at 11 months of age, at which time end-point histological and stereological analyses were performed.

FIGs. 2A and 2B are a pair of graphs showing that HSV amplicon-delivered A $\beta$  antigens elicit marked humoral responses. Helper virus-free HSV amplicons (1x10<sup>5</sup> transduction units) were delivered subcutaneously to APP<sub>Swe</sub>-overexpressing transgenic mice (Tg2576) at six weeks of age. Serum was obtained from each vaccinated mouse according to the schema illustrated in FIG. 1B, and 1:256 dilutions were analyzed by ELISA. Levels of antigen-specific antibodies arising from each vaccination were corrected using serum isolated from HSVlac control mice, and are expressed as "Corrected Absorbance @ 450 nm" for a subset of timepoints. FIG. 1A is a series of photomicrographs demonstrating that analysis of sera isolated from vaccinated mice by  $\alpha$ -A $\beta$  ELISA showed that both amplicon-expressed A $\beta$  immunogens were capable of eliciting A $\beta$ -specific humoral responses. Responses induced by the A $\beta$ /TtxFC immunogen elevated at most assay time points and were more durable than those elicited by HSVA $\beta$ . FIG. 2B is a graph showing that analysis of  $\alpha$ -TtxFC antibody titers by ELISA; TtxFC responses were specifically generated only in HSVA $\beta$ /TtxFC-vaccinated mice. Error bars represent standard deviation, while "\*" indicates statistical significance (P < 0.05) between HSVA $\beta$ /TtxFC and HSVA $\beta$  values at same timepoint.

FIGs. 3A-3F are graphs showing that the antibodies elicited by HSV amplicon-delivered A $\beta$ /TtxFC are more Th2-like and more mature than those elicited by HSVA $\beta$ . Isotypes of  $\alpha$ -A $\beta$  antibodies were determined by ELISA using sera obtained from vaccinated Tg2576 mice at the 4-month post-treatment timepoint. Levels of A $\beta$ -specific antibody isotypes arising from each vaccination were corrected using serum isolated from HSVlac control mice, and are expressed as "Corrected Absorbance @ 450 nm". Error bars represent standard deviation. Marked differences in isotypes were observed between animals receiving the two A $\beta$  immunogen forms. HSVA $\beta$ -treated mice harbored exclusively  $\alpha$ -A $\beta$  antibodies of the IgM class while the HSVA $\beta$ /TtxFC-immunized Tg2576 mice produced antibodies primarily of the IgG1 isotype, with detectable levels of the IgA class. In addition, there existed  $\kappa$  light chain bias in the  $\alpha$ -A $\beta$  antibody pool obtained from HSV $\beta$ /TtxFC-injected mice.

FIG. 4 is a graph showing that HSVA $\beta$ -vaccinated mice exhibit enhanced pro-inflammatory molecule expression profiles in the hippocampus, as assessed by quantitative real-time RT-PCR. Tg2576 and non-transgenic littermates received equal numbers of virions ( $1 \times 10^5$  transducing units) subcutaneously at 8 and 12 weeks of age and animals 5 were sacrificed one week after the final injection. Total RNA was isolated from microdissected hippocampus from one hemisphere of each mouse (n=4 per group). Levels of various pro-inflammatory molecule transcripts were determined using quantitative "real-time" RT-PCR, and values expressed as relative transcript level (mean  $\pm$  standard deviation) normalized to levels of a GAPDH internal control target. Injection of Tg2576 10 mice with HSVA $\beta$  led to a specific up-regulation of IFN- $\beta$  (A), IFN- $\gamma$  (B), IL-6 (C), MIP-2 (D), and TNF- $\alpha$  (E) transcripts as compared to HSVlac-vaccinated Tg2576 mice. HSVA $\beta$ -treated non-transgenic mice did not exhibit these enhanced pro-inflammatory transcript profiles. Assessment of TNF- $\beta$  (F) expression determined a positive trend in HSVA $\beta$ -vaccinated Tg2576 mice but the difference as compared to the HSVlac-treated cohort did 15 not reach significance. Similar analyses of HSVA $\beta$ /TtxFC-treated mice of either genotype showed only a statistically significant up-regulation of the chemokine MIP-2, while all other markers in the hippocampus of these animals remained similar to HSVlac controls. Error bars represent standard deviation, while "\*" indicates statistical significance (P < 0.05) between HSVA $\beta$  or HSVA $\beta$ /TtxFC and HSVlac control values.

FIGs. 5A and 5B are a pair of graphs showing that HSVA $\beta$ /TtxFC-treated Tg2576 20 mice exhibit altered plaque morphology and reduced numbers of small A $\beta$ -immunopositive deposits. To qualitatively and quantitatively assess brain-harbored A $\beta$  burden, Tg2576 mice and non-transgenic littermate controls (Non-Tg) receiving HSVlac (n=3) or HSVA $\beta$ /TtxFC (n=4) were sacrificed at 11 months of age, perfused, and brains processed 25 for immunocytochemical analysis. FIG. 5A is a graph of representative immunocytochemical staining with the  $\alpha$ -A $\beta$  antibody 6E10, of brain sections highlighted marked differences in the appearance of A $\beta$  deposits between HSVlac- and HSVA $\beta$ /TtxFC-vaccinated Tg2576 mice. Background staining in Non-Tg mice is also shown for comparison purposes. Brain-harbored A $\beta$  deposits appeared qualitatively 30 different in HSVlac-treated Tg2576 mice than in HSVA $\beta$ /TtxFC-immunized counterparts.

FIG. 5B is a graph showing quantitative morphometric analyses performed to enumerate differences in brain A $\beta$  plaque burden in 11 month-old Tg2576 mice. The numbers of 6E10-immunopositive deposits were determined for each of three deposit area ranges (50  $\mu\text{m}^2$  to 200  $\mu\text{m}^2$ , 200  $\mu\text{m}^2$  to 500  $\mu\text{m}^2$ , and deposit areas > 500  $\mu\text{m}^2$ ). HSVA $\beta$ /TtxFC 5 vaccination resulted in a decrement in numbers of deposits occupying the smallest area. Error bars represent standard deviation, while “\*” indicates statistical significance (P < 0.05) between HSVA $\beta$ /TtxFC and HSVlac values in same range of deposit size.

FIG. 6 is a table that summarizes mouse survival data.

#### DETAILED DESCRIPTION

10 While the etiology of AD is presently unknown, substantial experimental and pathological data indicate that proteins cleaved from the amyloid precursor protein (APP) are key participants in pathogenesis. These cleavage products, the A $\beta$  peptides, undergo a process termed fibrillogenesis, which leads to the formation of a series of structural intermediates that exhibit differential neurotoxicities. Accumulation of these pathogenic 15 A $\beta$  peptides via enhanced production and/or formation of proto-fibrillar intermediates leads to synaptic dysfunction and, eventually, to neuronal cell death (Hardy *et al.*, *Nat. Neurosci.* 1(5):355-358, 1998; Lambert *et al.*, *Proc. Natl. Acad. Sci. USA* 95(11):6448-6453, 1998; Miravalle *et al.*, *J. Biol. Chem.* 275(35):27110-27116, 2000). Data generated in animal models suggests that attempting to raise an immunological response against the A $\beta$  protein 20 leads to inflammation in the brain that can cause severe damage, and even death, in the subject. The current invention is based on an approach that delivers therapeutic benefits without such adverse side-effects (or with a tolerable level of adverse side-effects). One approach employs an A $\beta$ -based composition (e.g., a herpes virus amplicon particle or other delivery vehicle(s) that express an A $\beta$  protein and, optionally, an adjuvant and 25 immunomodulatory protein to skew the immune response away from a cytotoxic inflammatory T cell response). Such compositions, upon administration to a patient, can elicit an immune response against pathogenic forms of the A $\beta$  peptide, thereby inhibiting A $\beta$  accumulation and/or leading to the dissolution of A $\beta$ -containing aggregates. As noted above, this response can occur without potentiating brain inflammation. Utilizing virus 30 vector-based vaccination provides one means to elaborate A $\beta$ -specific immune responses

that can be optimally tailored to Alzheimer's disease. While the invention is not limited to particular delivery vectors, we expect our vectors, including the herpes virus amplicon particles, will be more predictable and efficacious than conventional peptide/adjuvant paradigms. Helper virus-free herpes simplex virus (HSV) amplicon vectors elicit vigorous transgene product-specific immune responses *in vivo* (Hocknell *et al.*, *J. Virol.* 76(11):5565-5580, 2002; Wang *et al.*, *Vaccine* 21(19-20):2288-22897, 2003; Willis *et al.*, *Hum. Gene Ther.* 12(15):1867-1879, 2001). Given its ease of manipulation, absence of immunosuppressive viral genes, ability to efficiently transduce antigen presenting cells, and large transgene capacity, the amplicon is a well-positioned platform on which to build an A $\beta$ -directed AD therapeutic. Any of the compositions of the invention, including those containing amplicon particles, can be used to test A $\beta$  antigens with differential immune activities in an animal model (e.g., a mouse model) of AD. Such models are useful for determining the mechanisms underlying vaccine-induced brain inflammation, and for analyzing various combinations of A $\beta$  proteins, adjuvants, and immunomodulatory proteins.

The invention is not limited to compositions that treat or prevent neurological disease (e.g., AD) by any particular mechanism, and a variety of mechanisms may underlie the ability of active A $\beta$ -directed immunization to reduce amyloid burden. For example, anti-A $\beta$  antibodies may directly inhibit and potentially reverse A $\beta$  fibrillogenesis by assisting in plaque solubilization (Bacska *et al.*, *J. Neurosci.* 22(18):7873-7878, 2002). If correct, then an ideal treatment should induce a strong antibody response, mainly of isotypes that can traverse the blood-brain barrier. Helper T cell function, normally required for an effective antibody response, should in that case be as limited as possible to Th2-biased responses, as a strong Th1 response carries the risk of inducing a local inflammatory response to the A $\beta$  antigen if T cells penetrate the blood/brain barrier for any reason (Becher *et al.*, *Glia* 29(4):293-304, 2000), and compositions of the invention can elicit such a response. In addition, anti-A $\beta$  antibodies may act to capture soluble A $\beta$ , thereby preventing its participation in seeding of extracellular plaques (DeMattos *et al.*, *Proc. Natl. Acad. Sci. USA* 98(15):8850-8855, 2001).

Complement activation by antibody/A $\beta$  antigen complexes may have either useful or deleterious effects in the context of AD immunotherapy – complement deposition may

assist in the dissolution of antigen/antibody complexes that develop in the plaques as a result of antibody binding (Miller and Nussenzweig, *Proc. Natl. Acad. Sci. USA* 72(2):418-422, 1975). In fact, amyloidogenic mice devoid of the complement component C3 exhibit markedly enhanced neurodegeneration and amyloid deposition, supporting an important 5 role of complement activation and innate immune responses in protection from A $\beta$ -mediated neurotoxicity (Wyss-Coray *et al.*, *Proc. Natl. Acad. Sci. USA* 99(16):10837-10842, 2002). Bard *et al.* have demonstrated that antibody isotypes proficient in activating phagocytic cells through Fc receptors were very effective in dissolving amyloid deposits in a mouse model of AD (Bard *et al.*, *Proc. Natl. Acad. Sci. USA* 100(4):2023-2028, 2003).

10 It is important to evaluate the antibody isotypes that are induced by candidate compositions, as this information may provide insight into the contribution of Th1 and Th2 T cells to the anti-A $\beta$  immune response. Isotype analysis of anti-A $\beta$  specific antibodies generated in Tg2576 mice receiving HSVA $\beta$  or HSVA $\beta$ /TtxFC demonstrated the fundamental roles that antigen context and molecular adjuvants play in the 15 generation of antibody isotypes. Molecular adjuvants, like TtxFC, appear to assist in expansion and maturation of humoral immune responses (Lu *et al.*, *Infect. Immun.* 62(7):2754-60, 1994). In studies related to the current invention, HSVA $\beta$ -vaccinated mice failed to switch from an immature IgM isotype to one considered more mature, while HSVA $\beta$ /TtxFC-treated mice effectively generated anti-A $\beta$  antibodies of the IgG1 20 class. Because IgG1 antibodies arise as a result of Th2 T cell participation, HSVA $\beta$ /TtxFC vaccination appears to have biased the anti-A $\beta$  humoral response by activating the Th2 arm.

Vaccine antigen-mediated stimulation and T cell-driven proliferation and 25 differentiation of naïve B cells results in the generation of antigen-specific memory B cells and plasma cells carrying somatically mutated immunoglobulin loci (Banchereau *et al.*, *Annu. Rev. Immunol.* 12:881-922, 1994; Manz *et al.*, *Nature* 388(6638):133-134, 1997; Slifka *et al.*, *Immunity* 8(3):363-372, 1998), and generation of optimal B 30 cell memory is a vital consideration when designing an A $\beta$ -based therapeutic treatment for humans. Bernasconi *et al.* have demonstrated that activation of the memory B cell component is required for long-lasting therapeutic action (Bernasconi *et al.*, *Science* 298(5601):2199-2202, 2002). Antigen-dependent "short-term serological memory"

mediated by plasma cells lasts only a few months, while “long-term serological memory” requires antigen-independent polyclonal activation and differentiation of memory B cells. In those experiments, co-delivery of adjuvant-like proteins during or after antigen-specific vaccination led to a population-wide activation and differentiation 5 of memory B cells with polyclonal specificities. Mouse models of AD demonstrate there is a memory response participating in the protective action and durability of the HSVA $\beta$ /TtxFC therapeutic treatment.

Immunization of Tg2576 mice with HSVA $\beta$  led to a high rate of mortality, death 10 that occurred approximately 1-2 weeks following the second vector inoculation. Subcutaneous injection of HSVA $\beta$  induced an adverse reaction, probably encephalitis, specifically within the brains of these mice. Quantitative real-time RT-PCR analysis of RNA isolated from the hippocampus was employed as a correlate of a 15 hyperinflammatory CNS state. These experiments revealed a statistically significant enhancement of pro-inflammatory molecule expression (IFN- $\beta$ , IFN- $\gamma$ , IL-6, MIP-2, and TNF- $\alpha$ ) in HSVA $\beta$ -vaccinated Tg2576 mice.

TNF- $\alpha$  is a potent cytokine produced by astrocytes, microglia, and neurons following pathological stress (Perry *et al.*, *Curr. Opin. Neurobiol.* 5(5):636-641, 1995). TNF- $\alpha$  promotes infiltration of inflammatory cells, modulates MHC class I expression (Lavi *et al.*, *J. Neuroimmunol.* 18(3):245-253, 1988), and induces the production of 20 other cytokines in the brain (Das and Potter, *Neuron* 14(2):447-56, 1995; Nilsson *et al.*, *Neurochem. Int.* 39(5-6):361-370, 2001). IFN- $\gamma$  is expressed by activated Th1 T 25 lymphocytes and NK cells (Boehm *et al.*, *Annu. Rev. Immunol.* 15:749-795, 1997; Farrar and Schreiber, *Annu. Rev. Immunol.* 11:571-611, 1993), and has been shown to activate microglial cells, up-regulate MHC class II antigens, promote leukocyte adhesion, and increase nitric oxide production by promoting the transcription of iNOS 30 in the brain (Colton *et al.*, *J. Neuroimmunol.* 40(1):89-98, 1992; Frei *et al.*, *Eur. J. Immunol.* 17(9):1271-1278, 1987; Hewett *et al.*, *Neurosci. Lett.* 164(1-2):229-232, 1993; Hickey and Kimura, *Science* 239(4837):290-292, 1988). IFN- $\beta$  stimulates macrophages and NK cells, possesses antiviral activity, and modulates MHC class I expression. The pro-inflammatory cytokine, IL-6, is secreted by stimulated monocytes and macrophages as well as by astrocytes, microglia, and Th2 T cells (Akira *et al.*, *Adv.*

*Immunol.* 54:1-78, 1993; Gradient and Otten, *Prog. Neurobiol.* 52(5):379-390, 1997). In the CNS, IL-6 triggers a cytokine cascade (Di Santo *et al.*, *Brain Res.* 740(1-2):239-244, 1996) and modulates the activation of infiltrating T cells (Taga and Kishimoto, *Annu. Rev. Immunol.* 15:797-819, 1997). MIP-2 is a chemokine that induces the 5 migration and margination of neutrophils and is typically produced by macrophages. Elaboration of all these major pro-inflammatory cytokines within the CNS of Tg2576 mice was observed as a result of HSVA $\beta$  vaccination. Given the potency of these molecules, up-regulation of all or even a subset of them would be expected to impart profound effects on immune cell activation, neuronal and glial function, and cellular 10 viability in Tg2576 mice (Giovannini *et al.*, *Neurobiol. Dis.* 11(2):257-274, 2002; Hauss-Wegrzyniak *et al.*, *Exp. Neurol.* 176(2):336-341, 2002). Understanding the mechanism whereby the HSVA $\beta$  vaccination paradigm specifically induces such a marked pro-inflammatory response in the brain could provide valuable insight into the severe inflammatory events observed in patients receiving the experimental AN-1792 15 vaccine (Orgogozo *et al.*, *Neurology* 61(1):46-54, 2003).

The HSV-1 amplicons employed in the studies below are encompassed by the invention and can be used to express any combination of the A $\beta$  proteins, adjuvants, and/or immunomodulatory proteins described herein. These delivery vehicles possess a number of advantages over other gene delivery platforms. First, the amplicon is not a live virus (as 20 are vaccinia, canarypox, *etc.*) and therefore, has an inherently safer *in vivo* profile. Second, compared to DNA delivery systems or most virus-based vectors, expression is directed from multiple episomal copies within each transduced cell, and the genome is maintained for a prolonged period in non-dividing cells such as antigen presenting cells (APCs). Third, the transgene size limit is larger (< 130 kb; (Wade-Martins *et al.*, *Nucleic Acids Res.* 27(7):1674-82, 1999; Wade-Martins *et al.*, *Mol. Ther.* 7(5):604-612, 2003; Wade-Martins 25 *et al.*, *Nature Biotechnol.* 19(11):1067-1070, 2001) than many other viral vectors providing an opportunity to co-express factors with known immunomodulating activity. And, the lack of encoded viral genes avoids the effects that wild-type herpes viruses typically use to evade the immune system, such as downregulation of MHC expression and antigen 30 processing, and inhibition of dendritic cell maturation (Salio *et al.*, *Eur. J. Immunol.* 29(10):3245-53, 1999; Thomas and Rouse, *Immunol. Res.* 16(4):375-86, 1997).

*Compositions:* The invention includes compositions that can be used to treat Alzheimer's disease and other disorders associated with unwanted production of A $\beta$  proteins. These compositions can include any of the A $\beta$  proteins described herein (e.g., a human A $\beta$  protein) and an adjuvant and/or immunomodulatory protein in a lyophilized form or suspended in a diluent suitable for administration to a patient (e.g., a buffered solution (e.g., PBS)). Also included are nucleic acid molecules that encode the A $\beta$  proteins described herein (e.g., nucleic acid molecules that are isolated from the nucleic acids they are flanked by in a natural setting), vectors containing those nucleic acids (e.g., the amplicon particles), and cells (e.g., cells isolated from an intact animal) that express the A $\beta$  proteins (e.g., antigen presenting cells such as dendritic cells).

More specifically, the compositions can include A $\beta$ <sub>1-40</sub>, A $\beta$ <sub>1-42</sub>, A $\beta$ <sub>1-43</sub>, HSVA $\beta$ , and HSVA $\beta$ /TtxFC. The A $\beta$  proteins can have a sequence found in nature, including wild-type, Dutch, and Iowa mutations. For example, the A $\beta$ <sub>1-42</sub> protein can have the sequence (from the N- to the C-terminus): Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-15 His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala (SEQ ID NO:26). The sequences of A $\beta$  proteins are known in the art (as are the sequences of the proteinaceous adjuvants and immunomodulatory proteins described herein). The nucleic acid molecules encoding the proteins described herein (i.e., the A $\beta$  proteins, proteinaceous adjuvants, and 20 immunomodulatory proteins) can be naturally occurring or may be degenerate variants.

Alternatively, or in addition (as the compositions can contain more than one type of A $\beta$  protein), the proteins can be antigenic variants of an A $\beta$  protein. For example, the compositions can include one or more fragments of an A $\beta$  protein having, for example, about 10-20 (e.g., 12, 15, or 18), 10-25 (e.g., 17, 19, 21, or 23), 10-30 (e.g., 11, 13, 20, 25, 25 26, 27, 28, 29, or 30), or 30-40 (e.g., 32, 33, 34, 35, 36, 37, 38, or 39) residues. The sequence of the A $\beta$  protein, regardless of length, can also vary from that found in nature. For example, the sequence may contain one or more substituted residues (e.g., conservative amino acid substitutions) so long as the protein remains capable of eliciting a desirable immune response against an amyloid plaque. The sequence may in fact be quite different 30 from that of a naturally occurring A $\beta$  protein.

The compositions of the invention can include, as noted above, molecular adjuvants capable of assisting in the expansion and maturation of humoral immune responses; see Lu *et al.*, *Infect. Immun.* 62(7):2754-2760, 1994), and biologically active fragments thereof, as well as any of the various vehicles (*e.g.*, an amplicon particle (*e.g.*, an HSV-1 amplicon), 5 viral vector (*e.g.*, retroviral or adenoviral vector), plasmid, YAC, or BAC) that can be employed to deliver the former compositions to targeted tissues (*e.g.*, brain tissue) and cells.

10  $\text{A}\beta$  proteins, adjuvants, and immunomodulatory proteins may be about 60%, 75%, 80%, or even 90% or more (*e.g.*, 95, 96, 97, 98, or 99%) identical to their naturally occurring counterparts and retain one or more of the biological activities of the full-length polypeptides of the invention. Such comparisons are generally based on an assay of biological activity in which equal concentrations of the polypeptides are used and compared. The comparison can also be based on the amount of the polypeptide required to reach 50% of the maximal stimulation obtainable.

15 As noted, functionally equivalent or biologically active variants (polypeptides or nucleic acids) can be those, for example, that contain additional or substituted components (amino acid residues or nucleotides, respectively). Substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, 20 a functionally equivalent polypeptide is one in which 10% or fewer of the amino acids in a full-length, naturally occurring polypeptide are replaced by conservative amino acid substitutions, and the functionally equivalent polypeptide maintains at least 50% of the biological activity of the full-length polypeptide. Conservative amino acid substitution refers to the substitution of one amino acid for another amino 25 acid of the same class (*e.g.*, valine for glycine, arginine for lysine, *etc.*).

30 Polypeptides that are functionally equivalent to polypeptides of the invention can be made using random mutagenesis on the encoding nucleic acids by techniques well known to those skilled in the art. It is more likely, however, that such polypeptides will be generated by site-directed mutagenesis (again using techniques well known to those skilled in the art). These polypeptides may have increased functionality or decreased functionality, but can be used to practice the methods of the

invention as long as they remain capable of eliciting a desired immune response and/or inhibiting the onset or progression of a sign or symptom of neurological disease (e.g., AD).

Mutations within the coding sequence of nucleic acid molecules of the invention can be made to generate variant genes that are better suited for expression in a selected host cell. For example, N-linked glycosylation sites can be altered or eliminated to achieve, for example, expression of a homogeneous product that is more easily recovered and purified from yeast hosts that are known to hyperglycosylate N-linked sites. To this end, a variety of amino acid substitutions at one or both of the first or third amino acid positions of any one or more of the glycosylation recognition sequences which occur, and/or an amino acid deletion at the second position of any one or more of such recognition sequences, will prevent glycosylation at the modified tripeptide sequence (see, for example, Miyajima *et al.*, *EMBO J.*, 5:1193, 1986).

The polypeptides of the invention can be expressed from the same delivery vehicle (particularly where that vehicle has the capacity of an amplicon particle) and may be fused to one another or to another polypeptide (e.g., a marker, a polypeptide that facilitates purification, or a polypeptide that increases the circulating half-life of a protein to which it is attached). For example, the polypeptide can be fused to a hexa-histidine tag to facilitate purification of bacterially expressed protein or a hemagglutinin tag to facilitate purification of protein expressed in eukaryotic cells. The A $\beta$  protein can be fused to all or part of an albumin polypeptide or an immunoglobulin (e.g., the Fc region of an IgG) in order to increase its circulating half life.

A fusion protein may be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht *et al.* allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (*Proc. Natl. Acad. Sci. USA*, 88: 8972-8976, 1991). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus

are loaded onto Ni<sup>2+</sup> nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

If desired, the polypeptides of the invention can be chemically synthesized (for example, see Creighton, "Proteins: Structures and Molecular Principles," W.H. Freeman & Co., NY, 1983), or, perhaps more advantageously, produced by recombinant DNA technology as described herein. For additional guidance, skilled artisans may consult Ausubel *et al.*, "Current Protocols in Molecular Biology, Vol. I," Green Publishing Associates, Inc., and John Wiley & Sons, Inc., NY, 1989, Sambrook *et al.* ("Molecular Cloning, A Laboratory Manual," Cold Spring Harbor Press, Cold Spring Harbor, NY, 1989), and, particularly for examples of chemical synthesis Gait, M.J. Ed. ("Oligonucleotide Synthesis," IRL Press, Oxford, 1984).

The delivery vehicles can include any of those used routinely in the art (e.g., plasmids with regulatory elements and the viral vectors described herein). The herpes virus amplicons (described further below) can be constructed using published U.S. patent applications as a guide (see, e.g., 20030027322, 20040105844, and 2004157299).

*Methods of Administration:* There are a variety of methods for successfully administering the compositions of the invention to a patient. They can be delivered to a patient orally or parenterally (e.g., by injection (e.g., intramuscular, intravenous, or subcutaneous injection)). The compositions can also be delivered to cells (e.g., cells within a patient or in tissue culture) using any of the gene delivery methods known in the art. These methods include direct injection, high-speed bombardment (e.g., by gene gun), and lipofection.

*Amplicons:* Helper virus-free systems for packaging herpesvirus particles, including those described herein, include at least one vector (herein, "the packaging vector") that, upon delivery to a cell that supports herpesvirus replication, will form a DNA segment (or segments) capable of expressing sufficient structural herpesvirus proteins that a herpesvirus particle will assemble within the cell. When the particle assembles, amplicon plasmids that may also be present, can be packaged within the particle as well. In packaging systems that employ helper viruses, amplicon plasmids rely on the helper virus function to provide the replication machinery and structural proteins necessary for

packaging amplicon plasmid DNA into viral particles. Helper packaging function is usually provided by a replication-defective virus that lacks an essential viral regulatory gene. The final product of helper virus-based packaging contains a mixture of varying proportions of helper and amplicon virions. Recently, helper virus-free amplicon

5 packaging methods were developed by providing a packaging-deficient helper virus genome via a set of five overlapping cosmids (Fraefel *et al.*, *J. Virol.* 70:7190-7197, 1996; see also U.S. Patent No. 5,998,208) or by using a bacterial artificial chromosome (BAC) that encodes for the entire HSV genome minus its cognate cleavage/packaging signals (Stavropoulos and Strathdee, *J. Virol.* 72:7137-7143, 1998; Saeki *et al.*, *Hum Gene Ther.* 9:2787-2794, 1998). Such cosmids can be used as the packaging vector in the methods described herein. Thus, the packaging vector can be a cosmid-based vector or a set of vectors including cosmid-based vectors that are prepared so that none of the viral particles used will contain a functional herpesvirus cleavage-packaging site containing sequence. This sequence, which is not encoded by the packaging vector(s), is referred to as the “*a*” sequence. The “*a*” sequence can be deleted from the packaging vector(s) by any of a variety of techniques practiced by those of ordinary skill in the art. For example, one can simply delete the entire sequence (by, for example, the techniques described in U.S. Patent No. 5,998,208). Alternatively, one can delete a sufficient portion of the sequence to render it incapable of packaging. Another alternative is to insert nucleotides into the site that

10 render it non-functional.

15

20

The core of the herpes virus particle is formed from a variety of structural genes that create the capsid matrix. It is necessary to have those genes for matrix formation present in a susceptible cell used to prepare particles. Preferably, the necessary envelope proteins are also expressed. In addition, there are a number of other proteins

25 present on the surface of a herpes virus particle. Some of these proteins help mediate viral entry into certain cells, and as this is known to those of ordinary skill in the art, one would know to alter the sequences expressed by the viral particle in order to alter the cell type the viral particle infects or improve the efficiency with which the particle

30 infects a natural cellular target. Thus, the inclusion or exclusion of the functional genes encoding proteins that mediate viral entry into cells will depend upon the particular use of the particle.

In addition to a packaging vector, the herpes virus amplicon systems described herein include an amplicon plasmid. The amplicon plasmid contains a herpes virus cleavage/packaging site containing sequence, an origin of DNA replication (ori) that is recognized by the herpes virus DNA replication proteins and enzymes, and a transgene 5 of interest (e.g., a nucleic acid sequence that encodes a therapeutically effective protein). This vector permits packaging of desired nucleotide inserts in the absence of helper viruses. In some embodiments, the amplicon plasmid contains at least one heterologous DNA sequence that is operatively linked to a promoter sequence (we discuss promoter and other regulatory sequences further below). More specifically, the 10 amplicon plasmid can contain one or more of the following elements: (1) an HSV-derived origin of DNA replication (ori) and packaging sequence ("a" sequence); (2) a transcription unit driven typically by the HSV-1 immediate early (IE) 4/5 promoter followed by an SV-40 polyadenylation site; and (3) a bacterial origin of replication and an antibiotic resistance gene for propagation in *E. coli* (Frenkel, *supra*; Spaete and 15 Frenkel, *Cell* 30:295-304, 1982).

Amplicon plasmids are dependent upon helper virus function to provide the replication machinery and structural proteins necessary for packaging amplicon plasmid DNA into viral particles. Helper packaging function is usually provided by a replication-defective virus that lacks an essential viral regulatory gene. The final 20 product of helper virus-based packaging contains a mixture of varying proportions of helper and amplicon virions. Recently, helper virus-free amplicon packaging methods were developed by providing a packaging-deficient helper virus genome via a set of five overlapping cosmids (Fraefel *et al.*, *J. Virol.* 70:7190-7197, 1996) or by using a bacterial artificial chromosome (BAC) that encodes for the entire HSV genome minus 25 its cognate cleavage/packaging signals (Stavropoulos and Strathdee, *J. Virol.* 72:7137-7143, 1998; Saeki *et al.*, *Hum. Gene Ther.* 9:2787-2794, 1998).

*Methods for generating helper virus-free Herpesvirus amplicons:* Generally, the methods of the invention are carried out by transfected a host cell with several vectors and then isolating HSV amplicon particles produced by the host cell (while the 30 language used herein may commonly refer to a cell, it will be understood by those of ordinary skill in the art that the methods can be practiced using populations (whether

substantially pure or not) of cells or cell types, examples of which are provided elsewhere in our description). The method for producing an hf-HSV amplicon particle can be carried out, for example, by co-transfected a host cell with: (i) an amplicon vector comprising an HSV origin of replication, an HSV cleavage/packaging signal, 5 and a heterologous transgene expressible in a cell; (ii) one or more vectors that, individually or collectively, encode all essential HSV genes but exclude all cleavage/packaging signals; and (iii) a vhs expression vector encoding a virion host shutoff protein. One can then isolate or purify (although absolute purity is not required) the HSV amplicon particles produced by the host cell. When the HSV amplicon 10 particles are harvested from the host cell medium, the amplicon particles are substantially pure (*i.e.*, free of any other virion particles) and present at a concentration of greater than about  $1 \times 10^6$  particles per milliliter. To further enhance the use of the amplicon particles, the resulting stock can also be concentrated, which affords a stock of isolated HSV amplicon particles at a concentration of at least about  $1 \times 10^7$  particles 15 per milliliter.

The amplicon vector can either be in the form of a set of vectors or a single bacterial-artificial chromosome ("BAC"), which is formed, for example, by combining the set of vectors to create a single, doublestranded vector. As noted above, methods for preparing and using a five cosmid set are disclosed in, for example, Fraefel *et al.* 20 (*J. Virol.*, 70:7190-7197, 1996), and methods for ligating the cosmids together to form a single BAC are disclosed in Stavropoulos and Strathdee (*J. Virol.* 72:7137-43, 1998). The BAC described in Stavropoulos and Strathdee includes a *pac* cassette inserted at a *Bam*HI site located within the *UL41* coding sequence, thereby disrupting expression of the HSV-1 virion host shutoff protein.

25 By "essential HSV genes", it is intended that the one or more vectors include all genes that encode polypeptides that are necessary for replication of the amplicon vector and structural assembly of the amplicon particles. Thus, in the absence of such genes, the amplicon vector is not properly replicated and packaged within a capsid to form an amplicon particle capable of adsorption. Such "essential HSV genes" have previously 30 been reported in review articles by Roizman (*Proc. Natl. Acad. Sci. USA* 11:307-113, 1996; *Acta Viroloica* 43:75-80, 1999). Another source for identifying such essential

genes is available at the Internet site operated by the Los Alamos National Laboratory, Bioscience Division, which reports the entire HSV-1 genome and includes a table identifying the essential HSV-1 genes. The genes currently identified as essential are listed in FIG. 3.

5 In other embodiments, a helper-free herpesvirus amplicon particle (e.g., an hf-HSV) can be generated by: (1) providing a cell that has been stably transfected with a nucleic acid sequence that encodes an accessory protein (alternatively, a transiently transfected cell can be provided); and (2) transfecting the cell with (a) one or more packaging vectors that, individually or collectively, encode one or more (and up to all) 10 HSV structural proteins but do not encode a functional herpesvirus cleavage/packaging site and (b) an amplicon plasmid comprising a sequence that encodes a functional herpesvirus cleavage/packaging site and a herpesvirus origin of DNA replication (ori). The amplicon plasmid described in (b) can also include a sequence that encodes a therapeutic agent. In another embodiment, the method comprises transfecting a cell 15 with (a) one or more packaging vectors that, individually or collectively, encode one or more HSV structural proteins (e.g., all HSV structural proteins) but do not encode a functional herpesvirus cleavage/packaging site, (b) an amplicon plasmid comprising a sequence that encodes a functional herpesvirus cleavage/packaging site, a herpesvirus origin of DNA replication, and a sequence that encodes an immunomodulatory protein 20 (e.g., an immunostimulatory protein), a tumor-specific antigen, an antigen of an infectious agent, or a therapeutic agent (e.g., a growth factor), and (c) a nucleic acid sequence that encodes an accessory protein.

The HSV cleavage/packaging signal can be any cleavage/packaging that packages the vector into a particle that is capable of adsorbing to a cell (the cell being 25 the target for transformation). A suitable packaging signal is the HSV- I "a" segment located at approximately nucleotides 127- 1132 of the a sequence of the HSV- I virus or its equivalent (Davison *et al.*, *J. Gen. Virol.* 55:315-331, 1981).

The HSV origin of replication can be any origin of replication that allows for 30 replication of the amplicon vector in the host cell that is to be used for replication and packaging of the vector into HSV amplicon particles. A suitable origin of replication is the HSV- I "c" region, which contains the HSV- I ori segment located at approximately

nucleotides 47-1066 of the HSV- I virus or its equivalent (McGeogh *et al.*, *Nucl. Acids Res.* **14**:1727-1745, 1986). Origin of replication signals from other related viruses (e.g., HSV-2 and other herpes viruses, including those listed above) can also be used.

The amplicon plasmids can be prepared (in accordance with the requirements

5 set out herein) by methods known in the art of molecular biology. Empty amplicon vectors can be modified by introducing, at an appropriate restriction site within the vector, a complete transgene (including coding and regulatory sequences).

Alternatively, one can assemble only a coding sequence and ligate that sequence into an empty amplicon vector or one that already contains appropriate regulatory sequences

10 (promoter, enhancer, polyadenylation signal, transcription terminator, *etc.*) positioned on either side of the coding sequence. Alternatively, when using the pHSVlac vector, the *LacZ* sequence can be excised using appropriate restriction enzymes and replaced with a coding sequence for the transgene. Conditions appropriate for restriction enzyme digests and DNA ligase reactions are well known in the art (see, e.g.,

15 Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Cold Spring Laboratory, Cold Spring Harbor, New York (1989); Ausubel *et al.* (Eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, NY, 1999 and preceding editions; and U.S. Patent No. 4,237,224).

The amplicon systems featured in these methods and others described herein

20 can all be modified so that the transgene carried by the amplicon plasmid is inserted into the genome of the host cell. Accordingly, the methods described herein can each include an additional step of introducing, into the host cell, a vector (which can be, but is not necessarily, a plasmid) that encodes an enzyme that mediates insertion of the transgene into the genome (this vector may be referred to herein as "an integration

25 vector"). The integration vector can be applied to a host cell *in vivo* or in culture at the same time that one or more of the components of the amplicon system (e.g. the packaging vector or amplicon plasmid) are administered to the host cell. The enzyme encoded by the integration vector can be a transposase, such as that encoded by

*sleeping beauty* or a biologically active fragment or mutant thereof (*i.e.*, a fragment or

30 mutant of the *sleeping beauty* sequence that facilitates integration of the transgene into the genome at a rate or to an extent that is comparable to that achieved when wild type

*sleeping beauty* is used). As this system represents a fundamental advance over those in which the amplicon plasmid is maintained outside the genome (and is therefore “diluted out” as cells divide), it has broad application. Methods in which an integration vector is used in the context of an amplicon system, particularly including the hf-HSV 5 systems described herein, can be carried out to treat patients with a wide variety of diseases or disorders associated with damage to nerves or neural cells (here, as in the methods described above, a “patient” is not limited to a human patient but can be any other type of mammal). For example, the patient can have damage to the spinal cord, Alzheimer’s disease, or learning or memory deficiencies. Any of the specific types 10 diseases or disorders involving nerve or neural cell damage (e.g., spinal cord injury, Alzheimer’s disease, learning or memory deficiencies) set out herein can be treated.

In addition, one can further modify the amplicon system to improve the safety of treatments in which an integration vector is administered. Frequent transposition events may lead to mutagenesis of the host genome and, possibly, even to proto- 15 oncogene activation (although there is no evidence that this will occur or is likely to occur; it is speculated that the amplicon might enhance the frequency of such events, as 10-15 copies of the transgenon are present within a single virion). To regulate the transposase component of the system more tightly, one could, for example, incorporate the *Sleeping Beauty* protein into the virion in the form of a fusion with an HSV 20 tegument protein. Alternatively, one could effect exogenous application of transposase protein with the transgenon-containing amplicon vector. Both approaches would prevent continued synthesis of *Sleeping Beauty* and thus, obviate additional catalysis of transposition. In yet another strategy, one could incorporate protein instability 25 sequences into the open reading frame to limit transposase half-life. The transposon in the integration vector should be compatible with sequences flanking the transgene in the amplicon plasmid. For example, where the transposon is of the *Sleeping Beauty* system, the amplicon vector can include a transgene (for integration) flanked by the *Sleeping Beauty* terminal repeats. Integrating forms of the HSV amplicon vector platform have been described previously. One form consists of an HSV amplicon 30 backbone and adeno-associated virus (AAV) sequences required for integration.

The amplicon vector used in any of the methods described herein can also include a sequence that encodes a selectable marker and/or a sequence that encodes an antibiotic resistance gene. Selectable marker genes are known in the art and include, without limitation, galactokinase, beta-galactosidase, chloramphenicol acetyltransferase, beta lactamase, green fluorescent protein (GFP), alkaline phosphate, *etc.* Antibiotic resistance genes are also known in the art and include, without limitation, ampicillin, streptomycin, spectromycin, *etc.* A number of suitable empty amplicon vectors have previously been described in the art including, without limitation, pHHSV1ac (ATCC Accession 40544; U.S. Patent No. 5,501,979; 5 Stavropoulos and Strathdee, *J. Virol.*, 72:7137-43, 1998), and pHENK (U.S. Patent No. 6,040,172). The pHHSV1ac vector includes the HSV-1 *a* segment, the HSV-1c region, an ampicillin resistance marker, and an *E. coli lacZ* marker. The pHENK vector includes the HSV-1 *a* segment, an HSV-1 *ori* segment, an ampicillin resistance marker, and an *E. coli LacZ* marker under control of the promoter region isolated from the rat 10 preproenkephalin gene (*i.e.*, a promoter operable in brain cells). The sequences encoding a selectable marker, the sequences encoding the antibiotic resistance gene (which may also serve as a selectable marker), and the sequences encoding the transgene, may be under the control of regulatory sequences such as promoter elements that direct the initiation of transcription by RNA polymerase, enhancer elements, and 15 suitable transcription terminators or polyadenylation signals. Preferably, the promoter elements are operable in the cells of the patient that are targeted for transformation. A number of promoters have been identified that are capable of regulating expression within a broad range of cell types. These include, without limitation, HSV immediate-early 4/5 (IE4/5) promoter, cytomegalovirus ("CMV") promoter, SV40 promoter, and 20 P-actin promoter. Likewise, a number of other promoters have been identified that can regulate expression within a narrow range of cell types. These include, without limitation, the neural-specific enolase (NSE) promoter, the tyrosine hydroxylase (TH) promoter, the GFAP promoter, the preproenkephalin (PPE) promoter, the myosin heavy chain (MHQ promoter), the insulin promoter, the cholineacetyltransferase (ChAT) 25 promoter, the dopamine  $\beta$ -hydroxylase (DBH) promoter, the calmodulin dependent kinase (CamK) promoter, the c-fos promoter, the c-jun promoter, the vascular 30

endothelial growth factor (VEGF) promoter, the erythropoietin (EPO) promoter, and the EGR- I promoter. The transcription termination signal should, likewise, be operable in the cells of the patient that are targeted for transformation. Suitable transcription termination signals include, without limitation, polyA signals of HSV genes such as the vhs polyadenylation signal, SV40 poly-A signal, and CW IE1 polyA signal.

Applying the information above in effective gene therapies for neural damage has been hampered by the lack of a safe and reliable vector that can be used to transduce nerve cells. Nerve cells are effectively post-mitotic. Although both 10 retroviral and adenoviral vectors have been employed in different clinical trials for gene therapy, both systems exhibit limitations (Uckert and Walther, *Pharmacol. Ther.* 63:323-347, 1994; Vile *et al.*, *Mol. Biotechnol.* 5:139-158, 1996; Collins, *Ernst Schering Research Foundation Workshop*, 2000; Hitt *et al.*, *Adv. Pharmacol.* 40:137-206, 1997; Kochanek, *Hum. Gene Ther.* 10:2451-2459, 1999). For example, the low 15 levels of integrin receptors for adenovirus on CLL cells mandates the use of very high adenovirus titers, preactivation of the CLL cell with IL-4 and/or anti-CD40/CD40L (Cantwell *et al.*, *Blood* 88:4676-4683, 1996; Huang *et al.*, *Gene Ther.* 4:1093-1099, 1997), or adenovirus modification with polycations to achieve clinically meaningful 20 levels of transgene expression (Howard *et al.*, *Leukemia* 13:1608-1616, 1999).

HSV amplicon particles can be used to transduce nerve cells (e.g., mouse, rat, 25 human, or other mammalian). Vectors can be constructed to encode  $\beta$ -galactosidase (by inclusion of the *lacZ* gene), B7.1 (also known as CD80), or CD40L (also known as CD154), and they can be packaged using either a standard helper virus (HSVlac, HSVB7.1, and HSVCD40L) or by a helper virus-free method (hf-HSVlac, hf-HSVB7.1, and hf-HSVCD40L). Cells transduced with these vectors have been studied 30 for their expression of heterologous genes. High rates of expression in these studies have indicated that this means of gene therapy is an efficacious and reliable means of delivering heterologous genes. These studies support the conclusion that HSV amplicons are efficient vectors for gene therapy, particularly of neurons, and that helper virus-free amplicon preparations are well suited for use in therapeutic compositions.

*Therapeutic Agents:* As noted, the hf-HSV amplicon particles described herein (and the cells that contain them) can express a heterologous protein (*i.e.*, a full-length protein or a portion thereof (*e.g.*, a functional domain or antigenic peptide) that is not naturally encoded by a herpesvirus). The heterologous protein can be any protein that 5 conveys a therapeutic benefit on the cells in which it, by way of infection with an hf-HSV amplicon particle, is expressed or a patient who is treated with those cells.

When used for gene therapy, the transgene encodes a therapeutic transgene product, which can be either a protein or an RNA molecule.

Therapeutic RNA molecules include, without limitation, antisense RNA, 10 inhibitory RNA (siRNA), and an RNA ribozyme. The RNA ribozyme can be either *cis* or *trans* acting, either modifying the RNA transcript of the transgene to afford a functional RNA molecule or modifying another nucleic acid molecule. Exemplary RNA molecules include, without limitation, antisense RNA, ribozymes, or siRNA to nucleic acids for huntingtin, alpha synuclein, scatter factor, amyloid precursor protein, 15 p53, VEGF, *etc.*.

Therapeutic proteins include, without limitation, A $\beta$ , A $\beta$ /TtxFC, TtxFC (and other molecular adjuvants capable of assisting in expansion and maturation of humoral immune responses; see (Lu *et al.*, *Infect Immun* 62(7):2754-60, 1994) (as noted above, any of the compositions of the present invention, or methods in which they are used, 20 can include biologically active (*e.g.*, therapeutically useful) antigenic fragments or variants (*e.g.*, substitution, deletion, or addition mutants) of A $\beta$ , A $\beta$ /TtxFC, TtxFC (and other molecular adjuvants capable of assisting in expansion and maturation of humoral immune responses), or other therapeutic proteins.

25 *Formulation and Administration of hf-HSV amplicon particles:* The hf-HSV amplicon particles described herein can be administered to patients directly or indirectly; alone or in combination with other therapeutic agents; and by any route of administration. For example, the hf-HSV amplicon particles can be administered to a patient indirectly by administering cells transduced with the vector to the patient. 30 Alternatively, or in addition, an hf-HSV amplicon particle could be administered directly. For example, an hf-HSV amplicon particle that expresses an HSVA $\beta$ /TtxFC

protein can be introduced into spinal cord tissue by, for example, introducing the vector into the tissue or into the vicinity of the tissue. Amplicon particles are described in the art; specific teachings regarding the manufacture and use of HSV amplicons can be found in U.S. Serial Nos. 09/997,848 and 10/296,551. These patent applications, and 5 any patent applications related to them by a claim of priority, are hereby incorporated by reference in the present patent application in their entirety.

Administration of HSV protein amplicons encoding HSVA $\beta$ /TtxFC provide therapeutic benefits in the form of prevention or lessening of symptoms of Alzheimer's disease, while not causing inflammation. The helper virus-free HSV vectors disclosed 10 herein can be administered in the same manner.

The herpesvirus amplicon particles described herein, and cells that contain them, can be administered, directly or indirectly, with other species of HSV-transduced cells (e.g., HSVA $\beta$  and HSVA $\beta$ /TtxFC transduced cells) or in combination with other therapies. Such administrations may be concurrent or they may be done sequentially. 15 Thus, in one embodiment, HSV amplicon particles, the vectors with which they are made (*i.e.*, packaging vectors, amplicon plasmids, and vectors that express an accessory protein) can be injected into a living organism or patient (e.g., a human patient) to treat, for example, spinal cord damage or Alzheimer's disease. In further embodiments, one or more of these entities can be administered after administration of a therapeutically 20 effective amount of another substance.

The concentrated stock of HSV amplicon particles is effectively a composition of the HSV amplicon particles in a suitable carrier. HSV amplicon particles can also be administered in injectable dosages by dissolving, suspending, or emulsifying them in physiologically acceptable diluents with a pharmaceutical carrier (at, for example, 25 about  $1 \times 10^7$  amplicon particles per ml). Such carriers include sterile liquids, such as water and oils, with or without the addition of a surfactant and other pharmaceutically and physiologically acceptable carriers, including adjuvants, excipients or stabilizers. The oils that can be used include those obtained from animals or vegetables, petroleum based oils and synthetic oils. For example, the oil can be a peanut, soybean, or mineral 30 oil. In general, water, saline, aqueous dextrose and related sugar solutions, glycols

(e.g., propylene glycol or polyethylene glycol) are preferred liquid carriers, particularly when the amplicon particles are formulated for administration by injection.

For use as aerosols, the HSV amplicon particles, in solution or suspension, can be packaged in a pressurized aerosol container together with suitable propellants, for 5 example, hydrocarbon propellants like propane, butane, or isobutene with conventional adjuvants. The particles can also be administered in a non-pressurized form such as in a nebulizer or atomizer.

*Other Methods of Administration:* In addition to gene therapy (e.g., using hf-HSV amplicons), the invention also includes administration of A $\beta$ , A $\beta$ /TtxFC, TtxFC (and other 10 molecular adjuvants capable of assisting in expansion and maturation of humoral immune responses), or other therapeutic proteins by other methods. These methods include direct injection of amplicon particles, nucleic acids or the polypeptides they encode into a target tissue or a fluid that contacts the target tissue (e.g., where the target tissue is within the brain, the amplicon particle can be injected into cerebrospinal fluid), introduction of cells 15 transduced by a nucleic acid or polypeptide of interest into target tissue (or, similarly, a fluid that contacts the target tissue), bombardment at high velocity of target tissue with amplicon particles, nucleic acids or polypeptides of interest, enhancing endogenous expression of one or more of the polypeptides of interest, as well as various other methods known to those of skill in the art. These methods are united by the result: delivery of 20 therapeutically effective amounts of HSVA $\beta$ /TtxFC to a targeted tissue (e.g., brain tissue).

*Methods of Treatment; Delivery To Target Tissue:* The compositions of the present invention (including amplicons that express HSVA $\beta$ /TtxFC, and cells that contain them) can be used to prevent or lessen symptoms of Alzheimer's disease. A patient can be treated 25 after they have been diagnosed with Alzheimer's disease. Alternatively, the compositions of the invention can be used to treat patients before symptoms of Alzheimer's have occurred. Thus, "treatment" can encompass prophylactic treatment.

HSV amplicon particles have been used to transduce motoneurons. The vectors can be constructed to encode  $\beta$ -galactosidase (by inclusion of the *lacZ* gene) and 30 HSVA $\beta$  or HSVA $\beta$ /TtxFC, and they can be packaged using either a standard helper virus (e.g., HSVlac, HSVB7.1, and HSVCD40L) or by a helper virus-free method (e.g., hf-HSVlac, hf-HSVB7.1, and hf-HSVCD40L). As Examples 1-3 demonstrate, HSV

amplicons are efficient vectors for gene therapy, and that helper virus-free amplicon preparations are well suited for use in therapeutic compositions.

*Formulation and Administration of hf-HSV amplicon particles:* The hf-HSV amplicon particles described herein can be administered to patients directly or indirectly; 5 alone or in combination with other therapeutic agents; and by any route of administration. For example, the hf-HSV amplicon particles can be administered to a patient indirectly by administering cells transduced with the vector to the patient. Alternatively, or in addition, an hf-HSV amplicon particle could be administered directly. For example, an hf-HSV amplicon particle that expresses HSVA $\beta$  or HSVA $\beta$ /TtxFC can be introduced into target 10 brain tissue by, for example, injecting the vector into the brain tissue or into the vicinity of the brain tissue.

While the compositions of the invention are not limited to those that exert a therapeutic benefit by any particular mechanism of action, administration of HSV amplicons encoding HSVA $\beta$ /TtxFC can alleviate or prevent the development of 15 symptoms of Alzheimer's disease.

The herpesvirus amplicon particles described herein, and cells that contain them, can be administered, directly or indirectly, with other species of HSV-transduced cells (e.g., cells transduced with immunomodulatory agents) or in combination with other therapies. Such administrations may be concurrent or they may be done 20 sequentially. Thus, in one embodiment, HSV amplicon particles, the vectors with which they are made (i.e., packaging vectors, amplicon plasmids, and vectors that express an accessory protein) can be injected into a living organism or patient (e.g., a human patient) to treat, for example, Alzheimer's disease. In further embodiments, one or more of these entities can be administered after administration of another 25 therapeutically effective composition.

*Testing For Successful Treatment:* After treatment using the compositions or methods of the invention, it is possible to test treated patients to assess treatment success. One of skill in the neurological arts would be well aware of the appropriate tests to measure treatment success (e.g., tests of balance, fine motor skill, and cognition). For example, a 30 patient treated for Alzheimer's disease can be assessed using standard cognitive tests of

brain function (e.g., learning and memory). In addition, high-definition imaging techniques (e.g., MRI) can be used to assess directly neural response to treatment.

*Kits:* The invention includes kits that can be used to maintain or increase neuronal plasticity, strengthen synaptic transmission, and improve memory or learning.

5 These kits can include all of the necessary reagents for carrying out the methods of the invention, and can include any of the compositions of the invention. In addition, kits can include detailed instructions for effective use. For example, a kit for treating Alzheimer's disease can include amplicons containing HSVA $\beta$  or HSVA $\beta$ /TtxFC, detailed instructions for administering the amplicons to the appropriate tissue, and 10 instructions for confirming the effectiveness of amplicon therapy.

15 *Model Organisms for Studying Alzheimer's Disease:* The invention includes methods for producing model organisms (e.g., mouse, rat) useful in studying Alzheimer's disease and methods of treating it. For example, as shown in Examples 1-3, a mouse model can be produced by delivering HSVA $\beta$  or HSVA $\beta$ /TtxFC treatment to a particular strain of mouse. One of the advantages of this invention is that such an organismic model of 20 Alzheimer's disease can be used to determine the relationship between A $\beta$  antigen structure/context and the elicitation of protective immune responses that prevent amyloid plaque deposition and/or lead to dissolution of pre-existing amyloid pathology.

Development of an immunotherapeutic approach for AD is an even more challenging 25 endeavor given the extant inflammatory state within the afflicted brain. Employing the HSV amplicon to modulate immune responses through different routes of inoculation, co-expression of various immunomodulating factors, and design of A $\beta$  pathogenic peptides with varying structural characteristics makes this a unique and advantageous approach to studying how to impede or reverse disease progression. This methodology, and the organismic model that makes it possible, not only affords the development of novel AD immunotherapeutics, but contributes to the mechanistic dissection of AD pathogenesis and the immune responses required to mediate protection.

## EXAMPLES

### Cell Culture

Baby hamster kidney (BHK) and RR1 cell lines were maintained as previously described (Lu and Federoff, *Hum. Gene. Ther.* 6:421-30, 1995). The NIH-3T3 mouse fibroblast cell line was originally obtained from American Type Culture Collection and maintained in Dulbecco's modified Eagle medium plus 10% fetal bovine serum.

### Amplicon Construction and Helper Virus-free Amplicon Packaging

The previously described HSVlac amplicon contains the coding sequence for *E. coli*  $\beta$ -galactosidase under the transcriptional control of the HSV immediate-early 4/5 gene promoter (Geller and Breakefield, *Science* 241:1667-9, 1988). The 126-bp sequence encoding A $\beta$ 1-42 was PCR-amplified using sequence-specific primers that contained Bam HI and Hind III restriction sites and cloned into the HSVPrPUC amplicon vector (Geller and Breakefield, *Science* 241:1667-9, 1988) to create HSVA $\beta$ .

The A $\beta$ 1-42 sense primer was 5'-  
CCCGAAGCTTACCATGGATGCAGAATTCCGACATGACTCAGG-3' (SEQ ID NO:1) and the A $\beta$ 1-42 sense primer was  
5'-CCCGAAGCTTACCATGGATGCAGAATTCCGACATGACT-CAGG-3' (SEQ ID NO:2). HSVA $\beta$ /TtxFC was constructed by PCR amplifying the 1356-bp tetanus toxin fragment C segment (TtxFC) using gene-specific primers that contained *Bam*HI and *Sac*I restriction sites and the resultant product was cloned into the HSVA $\beta$  vaccine vector. The TtxFC sense primer was 5'-  
GCGGGATCCAAAAATCTGGATTGTTGGGTTGATAAT-3' (SEQ ID NO:3) and the TtxFC antisense primer was 5'-CGACTGAGCTCTTAATCA-  
TTTGTCCATCCTTCATCTGT-3' (SEQ ID NO:4). The newly designed vectors were sequenced to confirm identity, and in the case of HSVA $\beta$ /TtxFC, to ensure the maintenance of translational reading frame between A $\beta$ 1-42 and TtxFC coding sequences. Amplicon stocks were prepared using a modified helper virus-free packaging method that has been described previously (Bowers *et al.*, *Gene. Ther.* 8:111-120, 2001). Vector titers were determined using expression- and transduction-based methodologies (Bowers *et al.*, *Mol. Ther.* 1(3):294-299, 2000).

Administration Paradigm and Serum Isolation

All animal housing and procedures were performed in compliance with guidelines established by the University Committee of Animal Resources at the 5 University of Rochester. Four to eight week-old APPSwe Tg2576 mice (Taconic, Germantown, NY) and non-transgenic littermates were vaccinated via the subcutaneous route with PBS vehicle or one of the following amplicons: HSVlac, HSVA $\beta$ 1-42, or HSVA $\beta$ 1-42/TtxFC. The vaccination schedule consisted of three separate monthly 10 injections. Blood was collected from the lateral tail vein one week after each injection, and then once per month for 8 subsequent months. The blood was allowed to clot, then placed at 4°C overnight to facilitate separation of the serum from the clot. The clots were removed and the serum centrifuged at 10,000 x g for 10 min. to pellet any remaining blood cells and debris. The clarified serum was transferred to a fresh tube 15 and stored at -20°C until analyzed by ELISA.

15

ELISA Analyses

Microtiter plates (Corning) were coated with 100 ng/ml amyloid b antigen (Tocris Cookson Inc., Ellisville, MO) in carbonate buffer, or 100 ng/ml tetanus toxin fragment C (Calbiochem, San Diego, CA) in PBS. Negative control wells were coated 20 with the appropriate buffer and 0.5% BSA w/v (Sigma, St. Louis, MO). Plates were then incubated at 37° C for 1 hr. Plates were subsequently washed 4 times with PBST (PBS + 0.1% Tween), blocked with PBST + 5% (w/v) non-fat dried milk and 0.5% (w/v) BSA (Sigma) for 15 min. at 37° C, and then incubated overnight at 4° C. The following day plates were washed 4 times with PBST followed by addition of sera, 25 added in duplicate, at dilutions of 1:128, 1:256, and 1:512 in PBS, or positive control antibodies of rabbit anti-A $\beta$  (1:5000; Chemicon International, Temecula, CA) or goat anti-tetanus toxin fragment C (1:5000; Accurate Chemical, Westbury, NY) to appropriate wells. The plates were subsequently incubated for 1 hr. at 37°C, then washed 10 times with PBST and blocked for 30 min. at 37°C. Plates were washed 4 30 times with PBST and the appropriate secondary antibodies were added (1:2000; goat anti-rabbit horseradish peroxidase (HRP), rabbit anti-goat HRP, or rabbit anti-mouse

HRP all from Jackson Laboratories, West Grove, PA), and plates incubated for 1 hr. at 37° C. Wells were washed 5 times with PBST and 5 ml of developer reagent (3'3'5'5'tetramethyl benzidine; Sigma) and 45 ml of phosphate citrate buffer (Sigma) was added. The plates were developed for 15 min. at 22° C, and reaction stopped with 5 50 ml of 2N sulfuric acid. The wells were analyzed at an absorbance wavelength of 450 nm using a Bio-Rad microplate reader (Hercules, CA).

#### Antibody Isotype Analysis

Detection of antibody isotype was completed using an isotype detection kit

10 Mouse Mono AB ID kit (Zymed Laboratories, San Francisco, CA) as performed by Petrushina *et.al.* (*Neurosci Lett* 338(1):5-8, 2003). Briefly 96-well microtiter plates (Corning) were coated with Aβ1-42 peptide (100 ng/μl; or 100 ng/ml; Tocris) in carbonate buffer overnight at 4° C. Endogenous peroxidase activity was quenched by treatment with 0.3% hydrogen peroxide in PBS for 30 minutes. Serum samples derived 15 from vaccinated mice were added to wells at a dilution of 1:256, and incubated for 30 min. at 37° C. Following 4 washes with PBST 1 drop of subclass-specific, rabbit anti-mouse antibody was added to each appropriate well, and subsequently incubated for 30 min. at 37° C according to manufacturer's instructions. Wells were washed 4 times with PBST and 50 ml of diluted HRP-conjugated, goat anti-rabbit IgG (H+L) was added to 20 each well. After a 30-min. incubation at 37° C and 4 washes with PBST, 5 ml of 3'3'5'5'tetramethyl benzidine (Sigma) and 45 ml of phosphate citrate buffer (Sigma) was added. The plates were developed for 15 min. at 22° C and then quenched with 50 ml of 2N sulfuric acid. Wells were read at a wavelength of 450 nm using a Bio-Rad microplate reader.

25

#### Quantitative Real-time RT-PCR Analysis of Pro-inflammatory Molecule Transcripts

RNA was isolated from frozen mouse hippocampal sections with TRIzol solution (Life Technologies Inc., Carlsbad, CA). Isolated RNA samples were treated 30 with DNaseI (Sigma) and extracted using a phenol:chloroform extraction and ethanol precipitation. One microgram of RNA was reverse transcribed to cDNA using AMV

Reverse Transcriptase (Roche Diagnostic Corp., Basel, Switzerland) and random hexamers in a single PCR cycle of 10 min. at 25°C, 60 min. at 42°C, and 10 min. at 70°C. cDNA was stored at -20°C until use in quantitative real-time PCR reactions. All TaqMan™ probes were synthesized and labeled with 5'-end FAM and 3'-end TAMRA dyes by Synthegen, LLC (Houston, TX). The GAPDH sense primer was 5'-ACTGGCATGGCCTTCCG-3' (SEQ ID NO:5), the GAPDH antisense primer was 5'-CAGGCGGCACGTCAGATC-3' (SEQ ID NO:6), and the GAPDH probe was 5'-TTCCTACCCCCAATGTGTCCGTCGT-3' (SEQ ID NO:7). The IFN- $\beta$  sense primer sequence was 5'- CCTGGAGCAGCTGAATGGAA-3' (SEQ ID NO:8), the IFN- $\beta$  antisense primer sequence was 5'-CCGTCATCTCCATAGGGATCTT-3' (SEQ ID NO:9), and the IFN- $\beta$  probe sequence was 5'-TCAACCTCACCTACAGGGCGGACTTC-3' (SEQ ID NO:10). The IFN- $\gamma$  sense primer sequence was 5'-TGAACGCTACACACTGCATCTTG-3' (SEQ ID NO:11), the IFN- $\gamma$  antisense primer sequence was 5'- GTTATTCAAGACTTCTAGGCTTCAATG-3' (SEQ ID NO:12), and the IFN- $\gamma$  probe sequence was 5'-TTTGCAGCTTCCATGG-CTGTTTC-3' (SEQ ID NO:13). The IL-6 sense primer sequence was 5'-CTGCAAGAGACTCCATCCAGTT-3' (SEQ ID NO:14), the IL-6 antisense primer sequence was 5'- AAGTAGGGAAGGCCGTGGTT-3' (SEQ ID NO:15), and the IL-6 probe sequence was 5'-CCTTCTGGGACTGATGCTGGT-GACA-3' (SEQ ID NO:16). The MIP2 sense primer sequence was 5'-CAAGAACATCCAAGCTGAGTGT-3' (SEQ ID NO:17), the MIP2 antisense primer sequence was 5'-TTTGACCGCCCTTGAGAGT -3' (SEQ ID NO:18), and the MIP2 probe sequence was 5'-CCCACTGCGCCCAGACAGAACAGTCAT-3' (SEQ ID NO:19). The TNF- $\alpha$  sense primer sequence was 5'-TCCAGGCGGTGCCTATGT -3' (SEQ ID NO:20), the TNF- $\alpha$  antisense primer sequence was 5'-CGATCACCCCGAAGTTCAAGTA -3' (SEQ ID NO:21), and the TNF- $\alpha$  probe sequence was 5'-CAGCCTTTCTCATTCCCTGCTTGT-GGC-3' (SEQ ID NO:22). The TNF- $\beta$  sense primer sequence was 5'-TTCCTCCCAATACCCC-TTCC-3' (SEQ ID NO:23), the TNF- $\beta$  antisense primer sequence was 5'-TGAAGTCCGG-ATACACAGACTT-3' (SEQ ID NO:24), and the TNF- $\beta$  probe sequence was 5'-TGTGCCT-CTCCTCAGTGCGCAGA (SEQ ID

NO:25). Each 25-ml PCR sample contained 2.5 ml of purified cDNA, 900 nM of each appropriate primer, 50 nM of matching probe, and 12.5 ml of 2X Applied Biosystems Master Mix. The thermocycler parameters included a 2-min. incubation at 50°C, a 10-min. denaturation step at 95°C, and 40 cycles of 95°C for 15 sec. and 60°C for 1 minute. Fluorescent intensity of each sample was detected automatically by the Perkin-Elmer Applied Biosystems Sequence Detector 7700 machine. Each run included a target-specific standard curve dilution series, and all results were normalized to the profiles obtained via the GAPDH primer/probe set that served as a loading control. Following the PCR run, real-time data were analyzed using Perkin-Elmer Sequence Detector Software version 1.9.1 and the standard curve values.

#### Imaging and Morphometric Analysis of Amyloid Deposits

Brains from Tg2576 mice and non-transgenic littermates were fixed by 4% paraformaldehyde trans-cardiac perfusions. The brains were removed, post-fixed overnight in 4% paraformaldehyde in PBS, transferred to a solution of 20% sucrose in PBS overnight, and finally transferred to a solution of 30% sucrose in PBS. Brains were coronally sectioned (30 mm) using a sliding microtome, and sections were stored in cryoprotectant until used for immunocytochemical analyses.

A $\beta$  immunocytochemistry was performed according to previously described methods with some modifications (Morgan *et al.*, *Nature* **408**(6815):982-985, 2000). Briefly, brain sections were washed with PBS for 2 hours to remove the cryoprotectant, then incubated with 3% H<sub>2</sub>O<sub>2</sub> in PBS for 20 minutes to quench endogenous peroxidase activity. Sections were then washed and blocked in PBS with 10% normal goat serum and 0.4% Triton X-100. The sections were subsequently incubated in PBS containing 1% normal goat serum, 0.4% Triton X-100, and the A $\beta$ -specific antibody 6E10 (1:2000; Signet, Dedham, MA). The sections were washed with PBS, followed by an incubation with goat anti-mouse, HRP-conjugated secondary antibodies (Jackson Laboratories, 1:1000) in PBS containing 1% normal goat serum and 0.4% Triton X-100. The sections were developed with a nickel-enhanced DAB reagent (Vector Laboratory, Burlingame, CA), mounted on slides, and coverslips applied. Each slide was coded and its identity concealed from the microscope operator. A $\beta$ -positive

deposits were visualized and images captured using an Olympus AX-70 microscope equipped with a motorized stage (Olympus, Melville, NY) and the MCID 6.0 Imaging software (Imaging Research, Inc.). Sections were tiled under 20X magnification such that an entire brain section could be compiled as single image. Approximately 400 5 images were captured via the tiling function of the MCID 6.0 software. Each tiled image was then analyzed using the automated target detection mode. Target criteria were established by pixel density and target area size. The pixel density was set with an upper (brighter) and lower (darker) threshold of 0.3500 ROD density and 0.7000 ROD density, then areas were established as a spatial criteria as 50 mm<sup>2</sup> to 200 mm<sup>2</sup>, 10 200 mm<sup>2</sup> to 500 mm<sup>2</sup>, or Area>500 mm<sup>2</sup>. The image was scanned and all non-plaque targets (e.g., blood vessels) which met the density and area criteria were manually removed, leaving only A<sub>β</sub>-containing deposits that fell into one of the three categories. This allowed the measurement of the total number of plaques and total target area scanned for each image.

15

#### Thioflavin S Histochemistry

Microtome-derived mouse brain sections (30 mm) were washed with PBS for 30 minutes to remove cryoprotectant. The sections were stained for 3 minutes with Modified Weigert's hematoxylin, and developed in running tap water for 30 seconds. 20 Sections were washed in deionized H<sub>2</sub>O twice for 3 minutes each. Sections were subsequently soaked in 5% acid alcohol solution, washed in tap water for 30 sec., and then rinsed again in deionized H<sub>2</sub>O twice for 3 minutes. Sections were incubated with Thioflavin S for 1 min. and washed twice for 3 minutes. each in running tap water. The stain was developed in acetic acid (50% v/v) for 15 minutes, and sections were 25 mounted and air-dried. Sections were viewed with confocal microscopy using FITC filters.

#### Statistical Analyses

Data were compared by ANOVA and student T-test post hoc tests. A probability of 30 P < 0.05 was considered statistically significant.

Generation of an A $\beta$ -specific Immune Response

Generation of an A $\beta$ -specific immune response in transgenic mouse AD models overexpressing human APP<sub>Swe</sub> (i.e., Tg2576; (Hsiao *et al.*, *Science* 274(5284):99-102, 1996)) requires a vaccination paradigm that overcomes immune tolerance. It has 5 previously been demonstrated that amplicon vectors expressing antigens via the IE4/5 promoter are capable of transducing cells involved in antigen presentation, and, consequently, elicit antigen-specific immune responses in naïve and tolerized mice (Hocknell *et al.*, *J. Virol.* 76(11):5565-5580, 2002; Wang *et al.*, *Hum. Gene Ther.* 13(2):261-273, 2002; Willis *et al.*, *Hum. Gene Ther.* 12(15):1867-1879, 2001). To 10 assess the feasibility of a HSV amplicon-based AD therapeutic treatment, two vectors were constructed and tested in the present study (FIG. 1A). The first amplicon expressed A $\beta$ <sub>1-42</sub> alone (HSV $\alpha$  $\beta$ ). A second amplicon vector was created that expressed A $\beta$ <sub>1-42</sub> fused with the molecular adjuvant tetanus toxin fragment C (HSV $\alpha$  $\beta$ /TtxFC) in an effort to overcome A $\beta$  tolerance in Tg2576 transgenic mice 15 (Monsonego *et al.*, *Proc. Natl. Acad. Sci. USA* 98(18):10273-10278, 2001), and to alter the type of immune response elicited. Fusion of TtxFC to heterologous antigens has been shown to break tolerance and assist in generation of humoral immune responses (Spellerberg *et al.*, *J. Immunol.* 159(4):1885-1892, 1997). A previously described vector, designated HSVlac, expressed *E. coli*  $\beta$ -galactosidase (HSVlac) and served as a 20 negative control vaccine (Geller and Breakefield, *Science* 241:1667-1669, 1988). Expression was confirmed by immunocytochemical analysis and amplicon plasmids were packaged into virions using a helper virus-free method (Bowers *et al.*, *Gene Ther.* 8:111-120, 2001).

Tg2576 mice overexpress APP with the Swedish mutation (APP<sub>Swe</sub>) that results 25 in enhanced generation and extracellular deposition of the A $\beta$ <sub>1-42</sub> peptide. Four to eight week-old Tg2576 mice and non-transgenic littermates received three subcutaneous (s.c.) inoculations of  $1 \times 10^5$  transduction units of one of the two vaccine vectors (HSV $\alpha$  $\beta$  or HSV $\alpha$  $\beta$ /TtxFC) or HSVlac control (see FIG. 1B for study design). Serum was collected from immunized mice one week post-vaccination and monthly thereafter. 30 Antibodies generated to A $\beta$ <sub>1-42</sub> peptide and to the fused TtxFC domain were separately assessed using ELISA (FIG. 2). Both HSV $\alpha$  $\beta$ - and HSV $\alpha$  $\beta$ /TtxFC-immunized

Tg2576 mice (FIG. 2A) and non-transgenic control animals (data not shown) elicited an appreciable humoral response against A $\beta$ <sub>1-42</sub>, particularly detectable following the second immunization. Anti-A $\beta$ <sub>1-42</sub> titers were statistically different between HSVA $\beta$  and HSVA $\beta$ /TtxFC treatment groups from 1 month post-immunization onward

5 (P<0.001), where HSVA $\beta$ /TtxFC immunization led to a more pronounced and sustained enhancement of antibody titers. Assessment of anti-TtxFC titers indicated that the humoral responses generated by HSV amplicon-mediated immunization were antigen-specific as only HSVA $\beta$ /TtxFC-treated mice showed evidence of anti-TtxFC antibodies (FIG. 2B). These data, in aggregate, demonstrated that HSV amplicon

10 vectors generate A $\beta$ -specific humoral responses in the setting of A $\beta$  tolerance and the fused TtxFC adjuvant domain markedly enhanced anti-A $\beta$  antibody titers.

Previous A $\beta$  peptide-based vaccination studies indicated that the elaboration of antibody isotypes arising from Th2 T-cell involvement (*i.e.*, IgG1) were effective in preventing A $\beta$  deposition within the brains of mice predisposed to extracellular amyloid pathology (Schenk *et al.*, *Nature* 400(6740):173-177, 1999; Town *et al.*, *J. Neuroimmunol.* 132(1-2):49-59, 2002). In addition, induction of Th1-related antibody isotypes (*i.e.*, IgG2a) is indicative of the elaboration of pro-inflammatory cytokines and concomitant activation of cytotoxic T cells which could exacerbate neuronal degeneration should such a response be elicited in the CNS compartment

15 (Furlan *et al.*, *Brain* 126(Pt 2):285-291, 2003). Immune sera obtained at the 4-month post-vaccination timepoint were examined to isotype the anti-A $\beta$  antibodies elaborated as a result of the HSVA $\beta$  and HSVA $\beta$ /TtxFC injection paradigms. Sera from HSVA $\beta$ /TtxFC-immunized Tg2576 mice possessed a significant level of anti-A $\beta$  specific antibodies of the IgG1 isotype, indicating that the Th2 T-cell population was

20 primarily responsible for the observed humoral response (FIG. 3). A smaller fraction of anti-A $\beta$  antibodies elicited as a result of HSVA $\beta$ /TtxFC vaccination was of the IgA isotype. Interestingly, anti-A $\beta$  antibodies detected in sera isolated from HSVA $\beta$ - injected Tg2576 mice were primarily of the IgM class, indicating a lack of humoral response maturation in this vaccination cohort.

An amplicon-specific, genotype-specific mortality effect was observed in this vaccination study. Four of six Tg2576 mice receiving subcutaneous injections of the HSVA $\beta$  amplicon died approximately one week following the second vaccination (FIG. 6). Just prior to death, the four HSVA $\beta$ -injected Tg2576 mice exhibited signs of 5 ataxia and eventually became moribund and died. One HSVA $\beta$ -vaccinated non-transgenic mouse and one HSVlac-injected Tg2576 mouse were sacrificed due to a housing cage accident. All remaining treated mice completed the study and exhibited normal behavior and weight gain. This outcome suggested that an autoimmune response had occurred in a vaccine- and genotype-specific manner due to vaccine- 10 elicited encephalitis described previously in mice and possibly similar to that observed in clinical trial subjects (Furlan *et al.*, *Brain* 126(Pt 2):285-291, 2003; Orgogozo *et al.*, *Neurology* 61(1):46-54, 2003).

#### Comparison of Inflammation Responses

15 New sets of mice were given the initial two vector injections as illustrated in FIG. 1, but all mice were sacrificed within a week following the second inoculation to assess the possibility that HSVA $\beta$  selectively induces an encephalitic state in the brains of Tg2576 mice. Total RNA was prepared from microdissected hippocampus derived from each mouse and used to assess pro-inflammatory molecule transcript expression 20 via quantitative "real-time" RT-PCR as a correlate of brain inflammation. This approach was employed previously to sensitively monitor cytokine and chemokine transcript expression within substructures of the rodent brain (Olschowka *et al.*, *Mol. Ther.* 7(2):218-227, 2003). Six pro-inflammatory molecules were selected for profiling based upon their potent activities within the brain: IFN- $\beta$ , IFN- $\gamma$ , IL-6, MIP-2, TNF- $\alpha$ , 25 and TNF- $\beta$  (FIG. 4). A majority of immunological targets that were analyzed (IFN- $\beta$ , IFN- $\gamma$ , IL-6, MIP-2, and TNF- $\alpha$ ) exhibited enhanced expression specifically within hippocampi of HSVA $\beta$ -vaccinated Tg2576 mice as compared to HSVlac-injected counterparts ( $P < 0.05$ ). MIP-2 expression was also significantly increased in HSVA $\beta$ /TtxFC-treated Tg2576 mice (FIG. 4D). TNF- $\beta$  levels trended higher but this 30 difference did not reach statistical significance (FIG. 4F). Pro-inflammatory molecule transcript expression was at or near baseline levels in the remaining treatment/genotype

groups. These results strongly suggested that HSVA $\beta$ -mediated vaccination of Tg2576 induced a vigorous inflammatory response within the brain, a condition that may have contributed to their mortality.

5 Amplicon Treatment and Amyloid Plaque Burden

To assess the effects of amplicon treatment on amyloid plaque burden, HSVA $\beta$ /TtxFC- and HSVlac-treated mice were sacrificed at 11 months of age and brains were processed for A $\beta$  immunohistochemistry and Thioflavin-S histochemistry. Microscopic inspection of A $\beta$  deposits (6E10-positive) in brains obtained from the two 10 treatment groups showed marked differences in "plaque" morphology (FIG. 5). HSVlac-immunized Tg2576 mice appeared to qualitatively harbor more A $\beta$  deposits that were densely stained with the 6E10 antibody (FIG. 5A). Conversely, brains of HSVA $\beta$ /TtxFC-treated Tg2576 mice showed evidence of A $\beta$  deposits that were more diffusely labeled by the 6E10 antibody. Enumeration of 6E10-positive A $\beta$  deposits by 15 quantitative morphometric analysis revealed differences in sizes of deposits susceptible to HSVA $\beta$ /TtxFC treatment (FIG. 5B). Deposits with areas between 50  $\mu\text{m}^2$  and 200  $\mu\text{m}^2$  were significantly reduced ( $P < 0.05$ ) in HSVA $\beta$ /TtxFC-treated Tg2576 mice as compared to those receiving the control treatment. The numbers of 6E10-positive 20 deposits encompassing larger areas were not found to statistically differ between the two treatment groups. Thioflavin-S histochemistry, which stains fibrillogenic structures, also highlighted significant differences in the fibrillogenic nature of amyloid deposits between HSVlac and HSVA $\beta$ /TtxFC-treated animals. Thioflavin-S-positive deposits in brains of HSVlac-immunized Tg2576 mice appeared larger and stained more intensely than those found in HSVA $\beta$ /TtxFC-treated counterparts. These data in 25 aggregate indicate that the HSVA $\beta$ /TtxFC treatment resulted in a highly Th2-like humoral response that imparted a significant inhibitory effect on A $\beta$  deposition in Tg2576 mice. Moreover, treatment via this approach did not induce severe brain inflammation as was overtly evident in HSVA $\beta$ -treated Tg2576 mice.

A human case study

An 83 year old woman is diagnosed by a physician as suffering from the initial stages of Alzheimer's Disease. Most strikingly, she exhibits noticeably worse memory than previously, and she has particular difficulty in remembering events that occurred 5 in the recent past. This causes much concern among her family, and makes it more difficult for her to live the independent life to which she is used.

Under supervision of her physician, the patient is injected subcutaneously in the upper right arm with HSVA $\beta$ /TtxFC. Over the next month, the patient's memory improves noticeably, and her ability to remember events in the recent past is especially 10 improved. Other symptoms of Alzheimer's disease are also noticeably ameliorated. Brain scans reveal a significant diminishment in the amount of amyloid plaques previously detected in her brain.

15 The patient's physician regularly assesses the patient, and repeats the treatment once every two to six months, depending on his assessment of his patient's progress in improving and maintaining her memory.

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Other embodiments may be found within the scope of the 20 following claims.